Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Vaxxas
Vaxxas
Activities:
Drug Delivery
Pharmaceutical
Dosage Forms
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Australian researchers use Nanopatch to deliver polio vaccine
About 40-times less polio vaccine needed using patch delivery compared with a needle and syringe
Drug Delivery
Vaxxas raises AS$25m to accelerate commercialisation of novel vaccine platform
Will advance a series of clinical programmes and develop a pipeline of new vaccine products for major diseases
Research & Development
Vaxxas research project aims to advance next-generation technology for polio vaccine delivery
World Health Organisation to fund the project
Drug Delivery
Vaxxas agrees Nanopatch collaboration with Merck
To develop the vaccine delivery technology for infection and oncology applications
Drug Delivery
Vaxxas appoints David Hoey as chief executive
Establishes operations in Boston, Massachusetts, US to expand access to global partners
Subscribe now